|Articles|October 1, 2003

FDA APPROVES CUBICIN

The FDA has approved Cubicin, a product of Cubist Pharmaceuticals that was formally called Cidecin, for treatment of complicated skin and structure infections caused by gram-positive bacteria.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

FDA APPROVES CUBICIN

Related Content

Nail Findings in Children Can Signal Systemic Disease, Review Finds

The Knowledge-Behavior Gap in Pediatric Sun Safety Gets New Data

Don't Be Rash: The Sturge-Weber Foundation's 40-Year Case for Early, Coordinated Care

Don't Be Rash: Rethinking Skin Disease in Down Syndrome

Addressing Unmet Needs in Infant Atopic Dermatitis With Roflumilast Cream 0.05%

Latest CME

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Trending on Dermatology Times

FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years

Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study

AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation

Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial

Health Canada Grants Priority Review to Birch Triterpenes for EB